Anthony F Shields Selected Research

Pancreatic Neoplasms (Pancreatic Cancer)

1/2021	Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
10/2020	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
1/2019	Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
1/2013	Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
8/2011	A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
6/2010	Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
6/2010	CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
12/2005	A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
6/2004	Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
12/2003	Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony F Shields Research Topics

Disease

76	Neoplasms (Cancer) 05/2022 - 10/2002
10	Adenocarcinoma 12/2021 - 01/2003
10	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 04/2003
10	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 12/2003
10	Colonic Neoplasms (Colon Cancer) 01/2021 - 04/2012
8	Microsatellite Instability 01/2022 - 10/2018
7	Neoplasm Metastasis (Metastasis) 10/2021 - 04/2014
7	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 01/2005
6	Breast Neoplasms (Breast Cancer) 06/2019 - 08/2008
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022 - 04/2014
3	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 09/2021 - 04/2009
3	Stomach Neoplasms (Stomach Cancer) 01/2021 - 02/2003
3	Rectal Neoplasms (Rectal Cancer) 10/2017 - 06/2014
3	Diarrhea 11/2015 - 02/2004
2	Disease Progression 09/2021 - 04/2009
2	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 01/2018
2	Carcinogenesis 01/2017 - 01/2003
2	Necrosis 01/2013 - 04/2009
1	Hypertension (High Blood Pressure) 01/2021
1	Polyps 01/2021
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2020

Drug/Important Bio-Agent (IBA)

12	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021 - 02/2004
11	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2003
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2003
10	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 12/2003
9	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
7	Capecitabine (Xeloda)FDA Link 10/2016 - 02/2004
7	ThymidineIBA 10/2016 - 01/2005
6	clevudineIBA 12/2017 - 01/2005
6	Gemcitabine FDA Link 01/2013 - 12/2005
5	Leucovorin (Folinic Acid)FDA Link 01/2021 - 04/2007
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2016 - 04/2007
4	Proteins (Proteins, Gene)FDA Link 05/2022 - 10/2018
4	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2013
4	LigandsIBA 01/2019 - 01/2018
4	Pharmaceutical PreparationsIBA 10/2018 - 04/2014
4	alovudineIBA 10/2018 - 06/2008
4	Glucose (Dextrose)FDA LinkGeneric 08/2015 - 10/2002
3	B7-H1 AntigenIBA 01/2022 - 01/2019
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2021 - 12/2005
3	Celecoxib (Celebrex)FDA Link 01/2021 - 12/2005
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2021 - 12/2005
3	Antineoplastic Agents (Antineoplastics)IBA 12/2016 - 02/2006
3	Cetuximab (Erbitux)FDA Link 12/2016 - 04/2012
3	FluoridesIBA 02/2015 - 04/2014
3	Carboplatin (JM8)FDA LinkGeneric 11/2009 - 02/2003
3	Paclitaxel (Taxol)FDA LinkGeneric 11/2009 - 02/2003
3	Cisplatin (Platino)FDA LinkGeneric 12/2005 - 12/2003
2	selinexorIBA 05/2022 - 12/2016
2	Sunitinib (Sutent)FDA Link 09/2021 - 04/2009
2	AntigensIBA 01/2021 - 01/2013
2	Bevacizumab (Avastin)FDA Link 01/2021 - 01/2017
2	Small Interfering RNA (siRNA)IBA 01/2019 - 01/2018
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 02/2008
2	Folic Acid (Vitamin M)FDA LinkGeneric 01/2019 - 01/2018
2	Formaldehyde (Formol)FDA Link 11/2018 - 01/2018
2	ParaffinIBA 11/2018 - 01/2018
2	liposomal doxorubicin (Doxil)FDA Link 10/2018 - 01/2005
2	gancotamabIBA 10/2018 - 08/2017
2	Dexamethasone (Maxidex)FDA LinkGeneric 10/2018 - 04/2014
2	Pemetrexed (MTA)FDA Link 10/2018 - 04/2014
2	ThymineIBA 12/2017 - 08/2008
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2017 - 01/2005
2	thymidine kinase 1IBA 01/2017 - 08/2008
2	Biological ProductsIBA 06/2014 - 01/2003
2	pyrimidineIBA 11/2009 - 06/2008
2	EnzymesIBA 02/2008 - 12/2005
1	sotorasibIBA 05/2022
1	MT 17IBA 01/2022
1	Calcibiotic Root Canal SealerIBA 10/2021
1	Phosphotransferases (Kinase)IBA 09/2021
1	Tyrosine (L-Tyrosine)FDA Link 09/2021
1	PerforinIBA 01/2021
1	Granzymes (Granzyme)IBA 01/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021
1	Interleukin-12 (IL 12)IBA 01/2021
1	CreatinineIBA 01/2021
1	Histone-Lysine N-MethyltransferaseIBA 01/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2020
1	thiamine triphosphorate (TTP)IBA 10/2020
1	CytokinesIBA 10/2020
1	Histones (Histone)IBA 01/2020
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2019
1	Pentetic Acid (DTPA)FDA LinkGeneric 01/2019
1	PEGPH20IBA 01/2019
1	folfirinoxIBA 01/2019
1	Chelating AgentsIBA 01/2019
1	AcidsIBA 01/2019
1	cabozantinibIBA 01/2019

Therapy/Procedure

34	Therapeutics 05/2022 - 02/2003
15	Drug Therapy (Chemotherapy) 01/2021 - 04/2003
8	Radiotherapy 01/2018 - 12/2003
7	Immunotherapy 01/2022 - 02/2015
4	Adjuvant Chemotherapy 01/2021 - 01/2013
3	Neoadjuvant Therapy 06/2019 - 11/2015
2	Chemoradiotherapy 06/2010 - 12/2003
2	Combination Drug Therapy (Combination Chemotherapy) 04/2005 - 02/2003
1	Oral Administration 05/2022